Back to top

Image: Bigstock

Zacks.com highlights: Covanta Holding, Altice USA, Incyte and Archrock

Read MoreHide Full Article

For Immediate Release

Chicago, IL – Jan 18, 2018 - Stocks in this week’s article include: Covanta Holding Corporation , Altice USA, Inc. (ATUS - Free Report) , Incyte Corp. (INCY - Free Report) and Archrock, Inc. (AROC - Free Report) .

Screen of the Week of Zacks Investment Research:

Discard These 4 Toxic Stocks or Sell Short for Profit

The secret behind successful investing is the proper identification of overhyped toxic stocks and the correctly priced ones. However, it is not easy to accurately pinpoint toxic stocks and abandon them at the right time to make some gains at the end.

Overblown toxic stocks are usually susceptible to outside shocks and loaded with a huge amount of debt. Also, the price of toxic stocks is unrealistically high. However, the inflated price of the toxic stocks is only short-lived as it is higher than its intrinsic value.

The unreasonably inflated price of toxic stocks can be due to either an irrational exuberance associated with them or some serious fundamental drawbacks inherent in the stock. Owning such bloated stocks for a long stretch of time can be harmful to investors and may result in huge loss of wealth.

Investors may gain from the correct identification of toxic stocks with the help of an investing strategy known as short selling. This strategy allows them to sell a stock first and then buy it when the price falls.

While short selling excels in bear markets, it typically loses money in bull markets.

So, identifying toxic stocks and discarding them at the right time is the key to protect your portfolio from big losses. Profits can be made by short selling them.

And that's what we're screening for today…

For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/289062/discard-these-4-toxic-stocks-or-sell-short-for-profit

Get the remaining stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and back testing software.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.

Follow us on Twitter:  https://twitter.com/zacksresearch

Join us on Facebook:  https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto

Company: Zacks.com

Phone: 312-265-9268

Email: pr@zacks.com

Visit: https://www.zacks.com/

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Incyte Corporation (INCY) - free report >>

Archrock, Inc. (AROC) - free report >>

Altice USA, Inc. (ATUS) - free report >>